Optimizing the pharmacology of statins: Characteristics of rosuvastatin

Atherosclerosis Supplements

Volumn 2, Issue 4, 2002, Pages 33-37

  Chapman, M John ^a   McTaggart, Fergus ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASTRAZENECA   (United Kingdom)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase; Lipid profile; Pharmacological properties; Pleiotropic effects; Tissue selectivity

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CELL INTERACTION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LEUKOCYTE; LIVER CELL; LIVER METABOLISM; NONHUMAN; PATIENT; PRIORITY JOURNAL; TISSUE; BLOOD; REVIEW;

CHOLESTEROL, LDL; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRIMIDINES; SULFONAMIDES;

EID: 1242296077     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00016-2     Document Type: Conference Paper

References (16)

1. Buckett L, Ballard P, Davidson R, Dunkley C, Martin L, Stafford J, McTaggart F. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41. Abstract MoP29:W6.
2. Smith G, Davidson R, Bloor S, Burns K, Calnan C, McAulay P, Torr N, Ward W, McTaggart F. Pharmacological properties of ZD4522 - a new HMG-CoA reductase inhibitor. Atherosclerosis 2000;151:39. Abstract MoP20:W6.
3. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292:2001;1160-1164.
4. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 87 (Suppl.):2001;28B-32B.
5. Data on file, AstraZeneca, 2000.
6. Nezasa K, Higaki K, Hasegawa H, Inazawa K, Takeuchi M, Yukawa T, McTaggart F, Nakano M. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis 2000;151:39. Abstract MoP21:W6.
7. Warwick MJ, Dane AL, Raza A, Schneck DW. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151:39. Abstract MoP19:W6.
8. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 2000;40:1056. Abstract 48.
9. McCormick AD, McKillop D, Bulters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y. ZD4522: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J Clin Pharmacol 2000;40:1055. Abstract 46.
10. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 88:(5):2001;504-508.
11. Paoletti R., Fahmy M., Mahla G., et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomised, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390.
12. Davidson M., Ma P., Stein E., Gotto A.M., Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275.
13. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia (abstract). European Atherosclerosis Society 72nd Annual Meeting, 20-23 May, 2001, Glasgow, Scotland. Atherosclerosis 2001;Suppl 2:90-1. Abstract P176.
14. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
15. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 19:1999;2894-2900.
16. Stalker T.J., Lefer A.M., Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 133:2001;406-412.